Osteosarkoma

01Pathophysiology

Osteosarcoma arises from malignant mesenchymal stem cells that differentiate into osteoblasts and directly produce osteoid, which is the immature, unmineralized bone matrix. This is the defining histologic feature and is what separates osteosarcoma from every other primary bone tumor. The tumor does not simply destroy bone; it actively forms abnormal bone. That is the single most important concept for identification.

The tumor has a strong predilection for the metaphysis of long bones, especially the distal femur, proximal tibia, and proximal humerus. The metaphysis is the region of most active bone growth, which explains why the peak incidence coincides with the adolescent growth spurt. During this period, rapid cell division in the growth plate creates a window of vulnerability for somatic mutations and malignant transformation. This is also why taller-than-average adolescents carry a slightly higher risk.

In older adults, osteosarcoma arises through a different mechanism. In these patients, the tumor develops secondary to Paget disease of bone, where chronically disordered bone remodeling leads to accumulated genetic damage. Prior radiation exposure is another recognized pathway, with radiation-induced osteosarcoma appearing years to decades after treatment.

At the genetic level, the two most commonly implicated tumor suppressor genes are RB1 (the retinoblastoma gene) and TP53 (associated with Li-Fraumeni syndrome). Loss of function in these genes removes critical cell cycle checkpoints, allowing uncontrolled osteoblast proliferation.

The pain that patients experience is caused by periosteal stretching and cortical destruction as the tumor expands outward from the medullary cavity. The classic "sunburst" appearance on imaging results from tumor-produced osteoid radiating outward through the cortex. The Codman triangle forms when the periosteum is lifted off the cortex by the expanding tumor, and reactive new bone is deposited at the angle between the elevated periosteum and the cortical surface. These imaging features are a direct visual representation of the underlying pathology.

Because osteosarcoma spreads hematogenously rather than via lymphatics, the most common site of metastasis is the lung. This is a frequently tested distinction: the absence of regional lymphadenopathy is a helpful clue that the bone tumor in the vignette is osteosarcoma (or Ewing sarcoma) rather than a metastatic carcinoma.

02Classification and Clinical Manifestation

Clinical manifestation follows a fairly consistent pattern regardless of subtype. The cardinal symptom is localized bone pain that is insidious in onset, dull or aching in character, progressively worsening over weeks to months, and often worse at night. Swelling develops as the tumor grows through the cortex. In some cases, a pathologic fracture through the weakened bone is the first event that brings the patient to medical attention. Systemic symptoms such as fever, weight loss, and fatigue are uncommon in localized disease but may appear with advanced or metastatic presentations.

03Diagnostic Workup

The workup for a suspected osteosarcoma begins with plain radiography, which is always the best initial test for any patient presenting with progressive bone pain and a palpable bony mass. The classic findings on X-ray are what the exam tests most heavily: a mixed lytic and sclerotic lesion centered in the metaphysis, an aggressive "sunburst" periosteal reaction (created by spicules of new bone radiating outward), and a Codman triangle (a triangular area of reactive periosteal elevation at the tumor margin). When these findings appear in an adolescent with knee pain, osteosarcoma is the working diagnosis until proven otherwise.

Once the X-ray raises suspicion, the next step is MRI of the entire affected bone (including the joint above and below). MRI is the best modality for determining the intramedullary extent of the tumor, involvement of surrounding soft tissues and neurovascular structures, and the presence of skip lesions (satellite tumor deposits within the same bone that are separated from the primary mass). This information is essential for surgical planning.

CT of the chest is performed for metastatic staging because the lungs are the most common site of distant spread. A bone scan is used to evaluate the entire skeleton for additional bony disease.

The most accurate (confirmatory) test is biopsy. A core needle biopsy or an open (incisional) biopsy must be performed by the surgeon who will later perform the definitive resection, because the biopsy tract must be placed in a location that can be excised with the tumor. The hallmark histologic finding is malignant osteoid produced by tumor cells. This differentiates osteosarcoma from other primary bone tumors. For example, Ewing sarcoma has small round blue cells without osteoid; chondrosarcoma produces cartilaginous matrix, not osteoid.

Serum ALP and LDH are not diagnostic on their own but carry prognostic weight. An elevated ALP at diagnosis reflects high tumor activity. Falling ALP after neoadjuvant chemotherapy suggests a good treatment response, while persistently elevated or rising ALP suggests treatment failure or recurrence.

04Management and Treatment

Acute management begins with completing the staging workup described above, followed by referral to a multidisciplinary team at a center experienced in musculoskeletal oncology. Treatment is never surgery alone. The current standard of care is a three-phase approach: neoadjuvant chemotherapy, surgery, then adjuvant chemotherapy.

Neoadjuvant (preoperative) chemotherapy uses the MAP regimen. High-dose methotrexate (typically $8-12g\mathrm{/}{m}^{2}8\{-\}12\backslash \; g/m^2$ per dose) is administered with leucovorin rescue to prevent folate deficiency toxicity. Doxorubicin (Adriamycin) is given at $75mg\mathrm{/}{m}^{2}75\backslash \; mg/m^2$ per cycle (cumulative lifetime dose must stay below $450mg\mathrm{/}{m}^{2}450\backslash \; mg/m^2$ to limit cardiotoxicity). Cisplatin is given at $120mg\mathrm{/}{m}^{2}120\backslash \; mg/m^2$ per cycle with aggressive hydration to prevent nephrotoxicity. This phase typically lasts about 10 weeks.

The purpose of neoadjuvant chemotherapy is threefold: it reduces tumor volume to improve surgical margins, it treats occult micrometastases that are assumed to be present at diagnosis, and it provides an in-vivo assessment of chemosensitivity. After the resected specimen is examined, the pathologist grades the percentage of tumor necrosis. Greater than or equal to 90% necrosis is considered a good histologic response and is associated with improved survival. Less than 90% necrosis indicates a poor response, and some protocols will intensify the adjuvant regimen by adding ifosfamide and etoposide.

Surgical resection is performed after the neoadjuvant phase. Limb-salvage surgery with wide excision is preferred when it is oncologically and functionally feasible. The tumor, biopsy tract, and a cuff of normal tissue are removed en bloc, and the defect is reconstructed with a metallic endoprosthesis or allograft. Amputation is reserved for cases where the tumor extensively involves the neurovascular bundle, where adequate surgical margins cannot be achieved, or where a functional limb cannot be preserved.

Adjuvant (postoperative) chemotherapy continues the MAP regimen for approximately 12 to 29 additional weeks. The total duration of chemotherapy (neoadjuvant plus adjuvant) is roughly 6 to 12 months depending on the protocol.

Radiation therapy plays a very limited role in osteosarcoma because the tumor is relatively radioresistant. It is reserved for unresectable or incompletely resected tumors and for palliation of symptomatic metastases.

Key contraindications and toxicities to monitor:

• Methotrexate: renal toxicity (requires alkaline urine, hydration, and leucovorin rescue); avoid in renal impairment; monitor serum methotrexate levels

• Doxorubicin: dose-dependent cardiotoxicity (dilated cardiomyopathy); cumulative dose limit of $450mg\mathrm{/}{m}^{2}450\backslash \; mg/m^2$; echocardiography monitoring required

• Cisplatin: nephrotoxicity (aggressive pre- and post-hydration), ototoxicity (sensorineural hearing loss), peripheral neuropathy

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on osteosarcoma questions is by confusing the location within the bone. Osteosarcoma is a metaphyseal tumor. Ewing sarcoma is diaphyseal. Giant cell tumor is epiphyseal. This single distinction is tested repeatedly, and the vignette will often describe the exact anatomic region of the lesion to see if you can match it to the correct diagnosis. If a question describes a destructive lesion at the "end of a long bone near the growth plate" in a teenager, think osteosarcoma. If it says "mid-shaft," think Ewing.

Another common trap is the periosteal reaction. A "sunburst" pattern or a Codman triangle points to osteosarcoma. An "onion-skin" (lamellated) periosteal reaction points to Ewing sarcoma. These terms function as near-instant identifiers, and the test expects you to recognize them without hesitation.

Students also make errors on management sequencing. The correct sequence is neoadjuvant chemotherapy first, then surgery, then adjuvant chemotherapy. A question that asks for the "next best step" after biopsy-confirmed osteosarcoma is testing whether you know to start chemotherapy before operating, not to proceed directly to amputation.

Finally, remember the bimodal age distribution. In a teenager, osteosarcoma is primary and associated with rapid bone growth. In an elderly patient, osteosarcoma is secondary and the question will contain clues pointing to Paget disease (elevated ALP, bowing of long bones, hearing loss, "cotton wool" skull appearance) or prior radiation. If the vignette describes an older adult with a destructive bone lesion and a history of Paget disease, the diagnosis is secondary osteosarcoma, not simply "worsening Paget disease."

The core competency being tested across all osteosarcoma questions is pattern recognition: linking the patient's age, the anatomic location within the bone, the radiographic pattern, and the histologic finding (malignant osteoid production) into a single, rapid diagnostic conclusion.